CHICAGO -- Treatment with investigational izalontamab brengitecan (iza-bren) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC), a randomized trial from China showed.
Median PFS by blinded independent central review (BICR) was 8.5 months with the bispecific antibody-drug conjugate (ADC) compared with 3.1 months with physician's choice of chemotherapy (HR 0.29, 95% CI 0.22-0.38, P<0.0001), reported Jiong Wu, MD, PhD, of Fudan University Shanghai Cancer Center, at the American Society of Clinical Oncology annual meeting.
Median OS was 15.9 months with iza-bren versus 12.5 months with chemotherapy (HR 0.60, 95% CI 0.42-0.85, P=0.0019).
"Iza-bren clearly demonstrated superior, and more durable, antitumor activity," Wu said, adding that the data "support iza-bren as a new standard of care for patients with pretreated metastatic triple-negative breast cancer."
Invited discussant Valentina Guarneri, MD, PhD, of the University of Padova in Italy, pointed out that "the significant overall survival benefit was captured despite subsequent [anti-cancer] therapy use, including ADCs, in the control arm."
